As structural biology tools and screening technologies advance, the GPCR super family continues to be a hot area of drug discovery, with the potential to treat a plethora of diseases. For the first time ever, the GPCRs-Targeted Drug Discovery Summit Europe came to London and overcame pharmacology challenges, advancing the next wave of GPCR drug discovery.

Leading European biopharma experts and trail-blazing opinion leaders of academia united under one roof at this inaugural Meeting to share data, discuss the latest advances in drug discovery. The Summit deconvoluted signalling bias, revealed novel targets for successful therapeutic interventions and fast-tracked structurally guided GPCR drug discovery across inflammatory, cardiovascular and metabolic indications and beyond.

The Summit brought together technical experts from Eli Lilly, AstraZenenca, Roche, ThirtyFiveBio, OMass Therapeutics and more, unlocking previously undruggable targets, revealing the significance of genetic variants of GPCRs, showcasing ground-breaking drug discovery tools and streamlining the translation of small molecules and biologics into clinically successful therapies.

Senior Scientists, Heads and Directors of Drug Discovery, Biology, Chemistry and Pharmacology joined for 3 days of technical and data driven case studies and discussions, enabling their teams to accelerate novel GPCR-targeted drug discovery.